Form 4: Myomo CMO Harry Kovelman Reports Stock Sale for Tax

Chief Medical Officer Harry Kovelman sold 10,442 shares of Myomo, Inc. to cover tax obligations related to RSU vesting.

Summary

• Harry Kovelman, Chief Medical Officer of Myomo, Inc., disposed of 10,442 shares of common stock.
• The transaction occurred on June 12, 2026, at a price of $1.20 per share.
• The sale was executed to satisfy tax withholding requirements following the vesting of restricted stock units on June 11, 2026.
• Following this transaction, Kovelman retains beneficial ownership of 90,541 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative and required for tax compliance.

Positives

• The transaction was a mandatory tax-related sale rather than a discretionary divestment of equity.

Negatives

• The transaction results in a reduction of the officer's direct equity stake in the company.

Risks

• Reliance on equity-based compensation may lead to periodic selling pressure on the stock price during vesting cycles.

Future Outlook

No forward-looking guidance provided in this filing.

Management Comments

• The sale was made solely to pay income taxes resulting from a vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that tax-related 'sell-to-cover' transactions are standard practice for corporate executives in the medical technology sector and do not typically signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation and tax compliance practices observed in small-cap healthcare companies.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a routine tax-related sell-to-cover.

Next Steps

• None mentioned.

Key Dates

Keywords

Myomo, MYO, Insider Trading, Form 4, Medical Technology, Equity Vesting